Scribe Therapeutics (SCRE) investor relations material

Executive summary

• Focused on developing in vivo CRISPR-based genetic medicines for cardiometabolic diseases, with lead candidate STX-1150 in Phase 1 trials targeting LDL-C reduction via epigenetic silencing of PCSK9.

• Initiated first-in-human Phase 1 trial of STX-1150, with preclinical data showing durable LDL-C reduction and no significant safety signals; advancing STX-1200 (LPA) and STX-1400 (APOC3) with over $25M in CIRM grants.

• Strategic collaborations with Eli Lilly and Sanofi provide non-dilutive funding and validate technology platforms.

• Completed an upsized IPO and concurrent private placement in July 2026, raising $155.5M gross ($140.7M net), with cash and equivalents of $43.0M as of June 30, 2026.

Financial highlights

• Collaboration revenue was $1.9M for Q2 2026, down 61% year-over-year, and $4.2M for the first half, down 81% year-over-year, due to reduced activity with Lilly and completion of Sanofi workplans.

• Net loss for Q2 2026 was $6.5M ($2.62 per share), compared to $9.9M ($4.08 per share) prior year, reflecting lower R&D and G&A expenses.

• Operating expenses for Q2 2026 were $11.3M, down from $16.5M in Q2 2025, driven by lower R&D and G&A costs following workforce reductions and program prioritization.

• Cash, cash equivalents, and investments totaled $43.0M as of June 30, 2026.

Outlook and guidance

• Cash on hand, plus $140.7M net proceeds from July 2026 IPO and private placement, expected to fund operations into the first half of 2029.

• Initial clinical data from the STX-1150 Phase 1 trial, including safety and LDL-C lowering activity, expected in H1 2027.

• Anticipates continued operating losses as clinical and preclinical programs advance; expects increased expenses for R&D, manufacturing, and public company operations.